- Page 1: Clinical Practice Guideline on type
- Page 4 and 5: A bibliographic record of this work
- Page 7 and 8: Table of Contents Presentation 9 Au
- Page 9 and 10: 11. Diabetic foot. Assessment, prev
- Page 11: Presentation Care practice is becom
- Page 16 and 17: 13. Which drug combination strategi
- Page 19 and 20: Summary of recommendations Defi nit
- Page 21 and 22: D CPG B B B B A daily single dose
- Page 23 and 24: A B CPG Hypertense patients with DM
- Page 25 and 26: Treatment for diabetic foot ulcers
- Page 27: 1. Introduction Effective care for
- Page 31 and 32: 3. Methodology Methodology. Evidenc
- Page 33 and 34: 4. Epidemiology and sanitary impact
- Page 35: However, the quality of the assista
- Page 38 and 39: 5.2. Risk factors for the developme
- Page 40 and 41: 5.2.8. Diet and alcohol Type of die
- Page 42 and 43: 5.2.12. Heart failure The associati
- Page 44 and 45: The ADA does not recommend it for c
- Page 46 and 47: Figure 1. DM 2 diagnostic algorithm
- Page 48 and 49: 46 CLINICAL PRACTICE GUIDELINES IN
- Page 50 and 51: 6.1. Impaired Fating Glucoseucose (
- Page 52 and 53: 1++ An intensive intervention on li
- Page 54 and 55: Different SRs (81-84) have assessed
- Page 56 and 57: 7.1.4. Other dietary interventions
- Page 58 and 59: Exchange system This system is base
- Page 60 and 61: duration and intensity). Performing
- Page 62 and 63: [RR 0.75 (CI 95%: 0.60-0.93)], and
- Page 64 and 65:
The optimum dose in most patients i
- Page 66 and 67:
without heart failure. In this stud
- Page 68 and 69:
B B B B Metillinides can play a ro
- Page 70 and 71:
Recommendations B A A B B B B When
- Page 72 and 73:
8.2. Insulin therapy 8.2.1. Associa
- Page 74 and 75:
Slow-acting insulin analogues vs. N
- Page 77 and 78:
9. Screening and treatment of macro
- Page 79 and 80:
The validity and applicability of a
- Page 81 and 82:
The RCTs and the meta-analysis are
- Page 83 and 84:
1+ In primary prevention, aspirin b
- Page 85 and 86:
9.5.2. Pharmacological treatment of
- Page 87:
Recommendations B/D A B CPG Patient
- Page 90 and 91:
incidence was 0.3% after the first
- Page 92 and 93:
it is believed that microalbuminuri
- Page 94 and 95:
Summary of evidence 1++ In hyperten
- Page 96 and 97:
An SR on drugs to treat diabetic ne
- Page 98 and 99:
(241), the response rate to placebo
- Page 101 and 102:
11. Diabetic foot. Assessment, prev
- Page 103 and 104:
11.2.2. Peripheral arterial disease
- Page 105 and 106:
11.4. Other preventive measures The
- Page 107 and 108:
B D CPG B Diabetic foot screening m
- Page 109 and 110:
11.5.4. Antibiotic treatment for in
- Page 111:
2+ The culture has a limited value
- Page 114 and 115:
• Promote healthy lifestyles: die
- Page 116 and 117:
In another recent RCT (289), sMBG w
- Page 118 and 119:
12.3. Contents and methods of an ed
- Page 120 and 121:
Assessment of self-management recor
- Page 122 and 123:
13.4. Referral criteria to medical
- Page 125 and 126:
Appendices Appendix 1. Levels of Ev
- Page 127 and 128:
Appendix 2. DM 2 diet Estimating ca
- Page 129 and 130:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 131 and 132:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 133 and 134:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 135 and 136:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 137 and 138:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 139 and 140:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 141 and 142:
GPL-1 Analogues Biguanides Glitazon
- Page 143 and 144:
Devices FLEXPEN (Novo Nordisk): OPT
- Page 145 and 146:
Treatment for an unconscious patien
- Page 147 and 148:
Appendix 6. Assessment of macro- an
- Page 149 and 150:
Appendix 8. Use of monofilament Mon
- Page 151 and 152:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 153 and 154:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 155 and 156:
CLINICAL PRACTICE GUIDELINE ON TYPE
- Page 157 and 158:
Indicators of final outcomes • Nu
- Page 159 and 160:
Impaired Glucose Tolerance (IGT): I
- Page 161 and 162:
IGT INSIGHT Trial IV LDL LH LIFE Tr
- Page 163 and 164:
Bibliography 1. Estrategia en diabe
- Page 165 and 166:
33. Iso H, Date C, Wakai K, Fukui M
- Page 167 and 168:
64. Screening for type 2 diabetes.
- Page 169 and 170:
97. Thomas DE, Elliott EJ, Naughton
- Page 171 and 172:
129. Lincoff AM, Wolski K, Nicholls
- Page 173 and 174:
157. Natarajan S, Liao Y, Cao G, Li
- Page 175 and 176:
185. de GG. Low-dose aspirin and vi
- Page 177 and 178:
214. Rahman M, Pressel S, Davis BR,
- Page 179 and 180:
245. NZGG. Management of type 2 dia
- Page 181 and 182:
279. Norris SL, Nichols PJ, Caspers